pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
The toxicological cause of the disease has been attributed to the neurotoxin ODAP which acts as a structural analogue of the neurotransmitter glutamate. Lathyrism can also be caused by deliberate food adulteration.
== Prognosis == A typical patient with severe McLeod syndrome that begins in adulthood lives for an additional 5 to 10 years. Patients with cardiomyopathy have elevated risk for congestive heart failure and sudden cardiac death. The prognosis for a normal life span is often good in some patients with mild neurological or cardiac sequelae.
However, production climbed markedly when another cigarette-making machine was developed in the 1880s by James Albert Bonsack, which vastly increased the productivity of cigarette companies, which went from making about 40,000 hand-rolled cigarettes daily to around 4 million. At the time, these imported cigarettes from the United States had significant sales among British smokers. In the English-speaking world, the use of tobacco in cigarette form became increasingly widespread during and after the Crimean War, when British soldiers began emulating their Ottoman Turkish comrades and Russian enemies, who had begun rolling and smoking tobacco in strips of old newspaper for lack of proper cigar-rolling leaf. This was helped by the development of tobaccos suitable for cigarette use, and by the development of the Egyptian cigarette export industry.
Sources: en.wikipedia.org
The cranium has two cartilaginous capsules each containing one large eye, which resembles those of fish. The cornea is formed from a translucent epidermal layer; the slit-shaped pupil forms a hole in the iris just behind the cornea. The lens hangs behind the pupil; photoreceptive retinal cells line the back. The pupil can expand and contract; a retinal pigment screens incident light in bright conditions. Some species differ in form from the typical body shape. Basal species, the Cirrina, have gelatinous bodies with two fins located above the eyes, an internal shell and mostly webbed arms that are lined with fleshy papillae or cirri underneath.
== Interactions == The CYP3A4 inhibitors ketoconazole and verapamil strongly increase exposure to gepirone, whereas lithium, paroxetine, and warfarin have no effect on exposure to gepirone. The CYP3A4 inducer rifampin profoundly decreases exposure to gepirone.
Breastfeeding, also known as nursing, is the process whereby breast milk is fed to an infant or toddler. Infants may suckle directly from the breast, or milk may be extracted with a breast pump and then fed to the infant. The World Health Organization (WHO) recommends that breastfeeding begin within the first hour of a newborn's birth and continue as the baby wants. Health organizations including the WHO recommend exclusively breastfeeding for six months; this means that no other foods or drinks—other than vitamin D supplement—are typically given. The WHO recommends then continuing breastfeeding with appropriate complementary foods for up to 2 years, and beyond. Exclusive breastfeeding rose from 37.0% to 47.4% between 2012 and 2024. Breastfeeding has a number of benefits to both the mother and the infant, that infant formula lacks. Increased breastfeeding to near-universal levels in low and middle income countries could prevent approximately 820,000 deaths of children under the age of five annually. Breastfeeding decreases the risk of respiratory tract infections, ear infections, sudden infant death syndrome (SIDS), and diarrhea for the baby, both in developing and developed countries. Other benefits have been proposed to include lower risks of asthma, food allergies, and diabetes. Breastfeeding may also improve cognitive development and decrease the risk of obesity in adulthood. Benefits for the mother include less blood loss following delivery, better contraction of the uterus, and a decreased risk of postpartum depression.
CIDP is a neurological disorder caused by an injury to the protective coating of the nerves as they leave the brain. However, this was almost immediately ruled out by his physicians as testing was already done against the possibility of CIDP. Leaving the paralysis to be a rare side effect of the clinical drug, Ibrutinib Joe was taking to control his blood cancer, only he hasn't been taking the medication since a blood clot almost killed him. Dr. Lisa Sanders suggests that his regaining feeling in his toes is a result of Joe being off the medication, as it could take up to a year for the medication to fully leave his body and for the nerves to rebuild themselves. This raises the issue that if Joe stays off the medication he might be able to walk again but if he doesn't get back on he will have nothing controlling his blood cancer. Dr. Lisa Sanders later published Ann’s story on the column and awaited the response from the audience. The audience presented with many possibilities but Ann’s doctors had tested and ruled them all out except for two. The first possibility is Lyme Disease which is an infection caused by bacteria transmitted through ticks. While Ann’s symptoms are not in line with that of Lyme Disease, the disease is known for causing all kinds of strange and interesting neurological problems. The second possibility is that Ann has a Functional Neurological Disorder, where simply her body is not transmitting the correct signals.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.